High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma

Haematologia

Volumn 32, Issue 4, 2002, Pages 377-387

  Salgami, Eleanna V ^a   Efstathiou, Stamatis P ^a   Vlachakis, Vasilios ^a   Sekara, Eleftheria V ^a   Syrigos, Konstantinos N ^a   Roussou, Paraskevi P ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Hodgkin's lymphoma; Prognosis; Serum interleukin 10

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; INTERLEUKIN 10; LACTATE DEHYDROGENASE; VINBLASTINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT FAILURE; TUMOR BIOPSY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SERUM ALBUMIN;

EID: 0038281412     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Huhn, R., Radwanski, E., O'Connell, S., Sturgill, M., Clarke, L., Cody, R., Affrime, M., Gulter, D., Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers, Blood 87, 699 (1996).
2. Cortes, J., Talpaz, M., Cabanillas, F., Seymour, J., Kurzrock, R., Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis, Blood 9, 2516 (1995).
3. Mosmann, T., Properties and functions of interleukin-10, Adv. Immunol. 56, 1 (1994).
4. Levy, Y., Brouet, J., Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein, J. Clin. Invest. 93, 424 (1994).
5. Finke, J., Ternes, P., Lange, W., Mertelsmann, R., Dölken, G., Expression of interleukin-10 in B lymphocytes of different origin, Leukemia 7, 1852 (1993).
6. Vockerodt, M., Haier, B., Buttgereit, P., Tesch, H., Kube, D., The Epstein-Barr Virus latent membrane protein 1 induces interleukin 10 in Burkitt's lymphoma cells but not in Hodgkin's cells involved p38 (SAPK2 pathway), Virology 280, 183 (2001).
7. Stasi, R., Zinzani, L., Galieni, P., Lauta, V., Damasio, E., Dispensa, E., Da Tura, S., Papa, G., Detection of soluble inteleukin-2 receptor and interleukin-10 in serum of patients with aggressive non Hodgkin's lymphoma. Identification of a subject at high risk of treatment failure, Cancer 74, 1792 (1994).
8. Pastore, C., Gaidano, G., Ghia, P., Fassone, L., Gilia, A., Gloghini, A., Buonainto, D., Gonella, S., Roncella, S., Carbone, A., Saglio, G., Patterns of cytokine expression in AIDS-related non Hodgkin's lymphoma, Br. J. Hematol. 103, 143 (1998).
9. Bohlen, H., Kessler, M., Sextro, M., Diehl, V., Tesch, H., Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of Interleukin-10 serum levels for Hodgkin's disease, Ann. Hematol. 79, 110 (2000).
10. Sarris, A., Kliche, K., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F., McLaughlin, P., Rodriguez, M., Romagnera, J., Fritsche, H., Witzig, T., Duvic, M., Andreeff, M., Cabanillas, F., Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival, Ann. Oncol. 10, 433 (2000).
11. Viviani, S., Motti, P., Bonfante, V., Verderio, P., Valagussa, P., Bonadonna, A., Elevated pretreatment serum levels of IL-10 are associated with poor prognosis in Hodgkin's disease; the Milan cancer institute experience, Med. Oncol. 17, 59 (2000).
12. Vener, C., Guffanti, A., Pomati, M., Colombi, M., Alietti, A., La Targia, M. L., Bamonti-Catena, F., Baldini, L., Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis, Leukemia Lymphoma 37, 333 (2000).
13. Vassilakopoulos, T., Nadali, G., Angelopoulou, M., Siakantaris, M., Dimopoulou, M., Kontopidou, F., Rassidakis, G., Doussis-Anagnostopoulou, I., Hatzioannou, M., Vaiopoulos, G., Kittas, C., Sarris, A., Pizzolo, G., Pangalis, G., Serum Interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma, Haematologica 86, 274 (2001).
14. Herbst, H., Foss, H., Samon, J., Aranjo, I., Klotzbach, H., Krause, H., Agathanggelou, A., Niedobitek, G., Stein, H., Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease, Blood 87, 2918 (1996).
15. Ohshima, K., Suzumina, J., Akamatu, M., Takeshita, M., Kikuchi, M., Human and viral interleukin-10 in Hodgkin's disease and its influence on CD4+ and CD8+ lymphocytes, Int. J. Cancer 62, 5 (1995).
16. Küppers, R., Hansmann, M., Rajewsky, K., Clonarity and germinal center B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease, Ann. Oncol. 9 (Suppl. 5), 517 (1998).
17. Taga, K., Tosato, G., IL-10 inhibits human T-cell proliferation and IL-2 production, J. Immunol. 149, 1143 (1992).
18. Carbone, P., Kaplan, H., Musshoff, K., Smithers, D., Tubiana, M., Report of the committee on Hodgkin's disease staging classification, Cancer Res. 31, 1860 (1971).
19. Lukes, R. J., Butler, J. J., The pathology and nomenclature of Hodgkin's disease, Cancer Res. 26, 1063 (1966).
20. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N. L., Armitage, J. O., Carter, W., Hoppe, R., Canellos, G. P., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, NCI Sponsored International Working Group, J. Clin. Oncol. 17, 1244 (1999).
21. SPSS. Statistical Package for the Social Sciences. Windows version, release 10.0. Chicago SPSS Inc. (2000).
22. Armitage, P., Berry, G., Statistical methods in medical research, 2nd edn. Blackwell, Oxford (1987).
23. Kaplan, E., Meier, P., Nonparametric estimation from incomplete observations, J. Am. Stat. Ass. 53, 457 (1958).
24. Cox, D. R., Regression models and life tables (with Discussion), J. R. Stat. Soc. B 34, 187 (1972).
25. Hosmer, D. W., Lemeshow, S., Applied survival analysis: regression modeling of time to event data. Wiley, New York, NY (1999).
26. Harrell, F. E., Lee, K. L., Mark, D. B., Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat. Med. 15, 361 (1996).
27. Firth, D., Bias reduction of maximum likelihood estimates, Biometrika 80, 27 (1993).
28. Benjamin, D., Park, C., Sharma, V., Human B cell interleukin 10, Leukemia Lymphoma 12, 205 (1994).
29. Straus, D. J., Gaynor, J. J., Myers, J., Merke, D. P., Caravelli, J., Chapman, D., Yahalom, J., Clarkson, B. D., Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy, J. Clin. Oncol. 8, 1173 (1990).
30. Proctor, S. J., Taylor, P., Mackie, M. J., Donnan, P., Boys, R., Lennard, A., Prescott, R. J., A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party, Leukemia Lymphoma 7, 17 (1992).
31. Ferme, C., Bastion, Y., Brice, P., Lederlin, P., Divine, M., Gabarre, J., Assouline, D., Ferrant, A., Berger, F., Lepage, E., Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study, Cancer 80, 1124 (1997).
32. Hasenclever, D., Diehl, V., A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease, N. Engl. J. Med. 339, 1506 (1998).
33. Axdorph, U., Sjöberg, J., Grimfors, G., Landgren, O., Porwit-MacDonald, A., Björkholm, M., Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease, Ann. Oncol. 11, 1405 (2000).
34. Dukers, D. F., Jaspars, L. H., Vos, W., Oudejans, J. J., Hayes, D., Cillessen, S., Middeldorp, J. M., Meijer, C. J., Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease, J. Pathol. 190, 143 (2000).
35. Sarris, A. H., Medeiros, L. J., Rassidakis, G., Nadali, G., Viviani, S., Vassilakopoulos, T. P., Giardini, R., Chilosi, M., Kittas, C., Angelopoulou, M., Herling, M., Hagemeister, F. B., Rodriguez, M. A., Ramaguera, J., McLaughlin, P., Ford, R., Gianni, M., Bonadonna, G., Pangalis, G. A., Pizzolo, G., Cabanillas, F., Bcl-2 expression in Hodgkin-Reed-Sternberg cells (HRS) of patients with classical Hodgkin's disease is associated with lower progression-free survival and survival, Blood 96 (Suppl. 1), 725a (2000).
36. Smolewski, P., Robak, T., Krykowski, E., Blasinska-Morawiec, M., Niewiadomska, H., Pluzanska, A., Chmielowska, E., Zambrano, O., Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution, Clin. Cancer Res. 6, 2120 (2000).
37. Barth, S., Klimka, A., Matthey, B., Haier, B., Kube, D., Tesch H., Diehl, V., Engert, A., Cytokine fusion-toxins show specific potency against Hodgkin lymphoma cells in vitro, Leukemia Lymphoma 29 (Suppl. 1), 107 (1998).